Nuplazid, an antipsychotic marketed for Parkinson's, targets the imbalance created by the massive loss of dopermergenic cells. https://www.ncbi.nlm.nih.gov/pmc

Nuplazid, an antipsychotic marketed for Parkinson's, targets the imbalance created by the massive loss of dopermergenic cells. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007714/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007714/ It certainly had a significant impact on a Parkinson's patient I knew (from regular expressions of and involvement with delusional hallucinations to relatively normal, organized behavior). Of course the loss of cells might be self reinforcing.